1Etemadifar M,Janghorbani M,Shaygannejad V,et al.Comparison of Betaferon,Avonex,and Rebif in treatment of relapsing-remitting multiple sclerosis.Acta Neurol Scand,2006,113:283-287.
2Vartanian T,Solberg Sorensen P,Rice G.Impact of neutralizing antibodies on the clinical efficacy of interferon beta in multiple sclerosis.J Neurol,2004,251 Suppl 2:Ⅱ25-Ⅱ30.
3Rudick RA,Cutter GR,Baier M,et al.Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients.Mult Scler,2005,11:626-634.
4Tremlett H,Paty D,Devonshire V,et al.Disability progression in multiple sclerosis is slower than previously reported.Neurology,2006,66:172-177.
5Sorensen PS,Fazekas F,Lee M.Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis:a metaanalysis.Eur J Neurol,2002,9:557-563.
6Martinelli Boneschi F,Rovaris M,Johnson KP,et al.Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis:meta-analysis of three double-blind,randomized,placebo-controlled clinical trials.Mult Scler,2003,9:349-355.
7Polman CH,O′Connor PW,Havrdova E,et al.A randomized,placebo-controlled trial of natalizumab for relapsing multiple sclerosis.N Engl J Med,2006,354:899-910.
4McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol, 2001, 50: 121-127.
5Muraro PA, Liberati L, Bonanni L, et al. Decreased integrin gene expression in patients with MS responding to interferon-beta treatment. J Neuroimmunol, 2004, 150: 123-131.
6Chernajovsky Y, Mory Y, Chen L, et al. Efficient constitutive production of human fibroblast interferon by hamster cells transformed with the IFN-beta 1 gene fused to an SV40 early promoter. DNA, 1984, 3 : 297-308.
7Randomised double-blind placebo-controlled study of interferon beta-1 a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet, 1998, 352: 1498-1504.
8Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS ( SPECTRIMS ) Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results. Neurology, 2001, 56: 1496- 1504.
9Saida T, Tashiro K, hoyama Y, et al. Interferon beta-1b is effective in Japanese RRMS patients: a randomized muhicenter study. Neurology, 2005, 64: 621-630.
10Papeix C, Vidal JS, de Seze J, et al. Immunosuppressive therapy is more effective than interferon in neuremyelitis optica. Mult Scler, 2007, 13 : 256-259.
